The invention is directed to therapeutically active hydroxamic acid derivatives of formula (I): ##STR1## wherein the substituents are as defined in the specification. These therapeutically active hydroxamic acid derivatives have high intrinsic activity against a broad spectrum of matrix metalloproteinases (MMPs), good oral bioavailability, and additionally inhibit tissue necrosis factor (TNF) production.
该发明涉及公式(I)的治疗活性羟基酰胺衍
生物:##STR1## 其中取代基如规范中所定义。这些治疗活性羟基酰胺衍
生物对广谱的基质
金属
蛋白酶(MMPs)具有高固有活性,口服
生物利用度良好,并且还抑制组织坏死因子(TNF)的产生。